Work

Results from a Phase II trial (AIRLEAF) of a cathepsin C (dipeptidyl peptidase 1) inhibitor, BI 1291583, in adults with non-cystic fibrosis bronchiectasis*

Year: 2025

Type: conference-paper

Study design: Clinical Trial

Source: Pneumologie

DOI: 10.1055/s-0045-1804560

Authors: J Chalmers, M Shteinberg, M Mall, A O'Donnell, H Watz, A Gupta, E Frahm, A Eleftheraki, J Rauch, S Chotirmall, A Armstrong, P Eickholz, N Hasegawa, W Sauter, P McShane

Institutions: University of Dundee, Carmel Medical Center, Charité - Universitätsmedizin Berlin, Georgetown University Medical Center, German Center for Lung Research, LungenClinic Grosshansdorf, Boehringer Ingelheim (Germany), Nanyang Technological University, University of California, Los Angeles, Goethe University Frankfurt, Keio University, The University of Texas Health Science Center at Tyler

Language: English

Topic: Cystic Fibrosis Research Advances

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4408555909

FWCI:

Cites:

Cited by:

Related to: 10